Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 49

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 49
---
 applied to comparable products to those being developed by the Company; the descriptions
of the results of such preclinical studies and clinical trials contained in the SEC Reports are accurate and complete in all material
respects, and, except as set forth in the SEC Reports, the Company has no knowledge of any other clinical trials or preclinical studies,
the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the SEC
Reports when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence
from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any
preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the SEC Reports or the results of
which are referred to in the SEC Reports.

(hhh) .
The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended,
that are effective as of the date hereof and as of each Closing Date, and any and all applicable rules and regulations promulgated by
the Commission thereunder that are effective as of the date hereof and as of each Closing Date.

(iii) . The foregoing
representations and warranties shall survive the Closing.

3.2 . Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date
hereof and as of each Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):

(a) .
Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws
of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power
and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its
obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the
transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability
company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly
executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms here